BRPI0915446A2 - combinação de um antagonista de c-met e um composto de amino-heteroarila para o tratamento de câncer - Google Patents

combinação de um antagonista de c-met e um composto de amino-heteroarila para o tratamento de câncer

Info

Publication number
BRPI0915446A2
BRPI0915446A2 BRPI0915446A BRPI0915446A BRPI0915446A2 BR PI0915446 A2 BRPI0915446 A2 BR PI0915446A2 BR PI0915446 A BRPI0915446 A BR PI0915446A BR PI0915446 A BRPI0915446 A BR PI0915446A BR PI0915446 A2 BRPI0915446 A2 BR PI0915446A2
Authority
BR
Brazil
Prior art keywords
combination
cancer treatment
met antagonist
aminoheteroaryl compound
aminoheteroaryl
Prior art date
Application number
BRPI0915446A
Other languages
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0915446A2 publication Critical patent/BRPI0915446A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0915446A 2008-07-08 2009-07-08 combinação de um antagonista de c-met e um composto de amino-heteroarila para o tratamento de câncer BRPI0915446A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12959808P 2008-07-08 2008-07-08
EP20080305387 EP2143441A1 (en) 2008-07-08 2008-07-08 Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PCT/EP2009/058709 WO2010003992A1 (en) 2008-07-08 2009-07-08 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0915446A2 true BRPI0915446A2 (pt) 2015-11-10

Family

ID=39924962

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915446A BRPI0915446A2 (pt) 2008-07-08 2009-07-08 combinação de um antagonista de c-met e um composto de amino-heteroarila para o tratamento de câncer

Country Status (15)

Country Link
US (3) US8623359B2 (pt)
EP (2) EP2143441A1 (pt)
JP (1) JP5677949B2 (pt)
KR (1) KR20110043548A (pt)
CN (1) CN102083465B (pt)
AU (1) AU2009268040B2 (pt)
BR (1) BRPI0915446A2 (pt)
CA (1) CA2730110C (pt)
ES (1) ES2668970T3 (pt)
GE (1) GEP20135829B (pt)
IL (1) IL210404A (pt)
MA (1) MA32458B1 (pt)
MX (1) MX2011000255A (pt)
RU (1) RU2526171C2 (pt)
WO (1) WO2010003992A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR086823A1 (es) * 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
KR102306656B1 (ko) * 2013-07-03 2021-09-29 삼성전자주식회사 항 c-Met 항체를 이용하는 암의 병용 치료
CN105745335A (zh) * 2013-08-14 2016-07-06 佳根曼斯菲尔德有限公司 用于对cMET核酸进行多模态分析的组合物及方法
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR741285A (pt) 1932-08-22 1933-02-08
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
PL1959955T3 (pl) * 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
RU2608644C2 (ru) * 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет

Also Published As

Publication number Publication date
WO2010003992A8 (en) 2011-02-10
MX2011000255A (es) 2014-04-16
WO2010003992A1 (en) 2010-01-14
IL210404A0 (en) 2011-03-31
AU2009268040A1 (en) 2010-01-14
EP2315601B1 (en) 2018-02-14
KR20110043548A (ko) 2011-04-27
CA2730110C (en) 2018-10-02
CN102083465B (zh) 2015-05-27
CN102083465A (zh) 2011-06-01
US8623359B2 (en) 2014-01-07
US9375425B2 (en) 2016-06-28
IL210404A (en) 2017-06-29
MA32458B1 (fr) 2011-07-03
JP2011527313A (ja) 2011-10-27
GEP20135829B (en) 2013-05-27
RU2526171C2 (ru) 2014-08-20
US20150250780A1 (en) 2015-09-10
CA2730110A1 (en) 2010-01-14
EP2143441A1 (en) 2010-01-13
ES2668970T3 (es) 2018-05-23
EP2315601A1 (en) 2011-05-04
AU2009268040B2 (en) 2014-11-20
US20110117098A1 (en) 2011-05-19
JP5677949B2 (ja) 2015-02-25
US20140186356A1 (en) 2014-07-03
RU2011103125A (ru) 2012-08-20
US9011865B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
BRPI0915446A2 (pt) combinação de um antagonista de c-met e um composto de amino-heteroarila para o tratamento de câncer
CY2020036I2 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
CY2020014I1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
PT2340042E (pt) Métodos e composições para o tratamento de cancro
IL196470A (en) Antagonist antibody for the treatment of cancer
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
EP2303021A4 (en) COMPOSITIONS FOR CANCER TREATMENT
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0921802A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
DK2121139T3 (da) Formulations for cancer treatment
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0906391A2 (pt) Máscara higiênica para proteção de outros
PT2632452T (pt) Compostos e composições para o tratamento do cancro
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2326651T3 (da) Buprenorphinanaloger
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
EP1987838A4 (en) NEW CONNECTION TO TUMOR THERAPY
BRPI0813670A2 (pt) Compostos para tratamento
EP2283862A4 (en) ANTITUMOR AGENT
HUS1600039I1 (hu) Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL